Insider · CIK 0001693564

Lyons-Williams Lori

Reports to the SEC for 4 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001693564

Forms 4 and 5

Insider transactions

41 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-26	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+19K sh	—	—	19,000
2026-03-03	RAPTRAPT Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−4,956 sh	—	—	0
2026-03-03	RAPTRAPT Therapeutics, Inc. · Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−32.2K sh	—	—	0
2026-03-03	RAPTRAPT Therapeutics, Inc. · Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−4,561 sh	—	—	0
2026-03-03	RAPTRAPT Therapeutics, Inc. · Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,618 sh	—	—	0
2026-03-03	RAPTRAPT Therapeutics, Inc. · Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−1,063 sh	—	—	0
2026-03-03	RAPTRAPT Therapeutics, Inc. · Director Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−2,813 sh	—	—	0
2026-01-30	RAPTRAPT Therapeutics, Inc.A Award	Director	AAward	+4,956 sh	—	—	4,956
2025-06-26	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+14.8K sh	—	—	14,750
2025-05-29	RAPTRAPT Therapeutics, Inc. · Director Stock Option (right to buy)A Award	Director	AAward	+258K sh	—	—	257,832
2024-05-24	CTNMContineum Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+29.5K sh	—	—	29,500
2024-05-22	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+36.5K sh	—	—	36,490
2023-05-24	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.9K sh	—	—	12,940
2022-05-25	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+8,500 sh	—	—	8,500
2021-11-09	RAPTRAPT Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2021-04-16	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2021-04-16	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	—	—	0
2020-05-14	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2020-02-20	Dermira, Inc.Restricted Stock UnitD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−15K sh	—	—	0
2020-02-20	Dermira, Inc.D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−25.4K sh	$18.75	−$476K	0
2020-02-20	Dermira, Inc.Employee Stock Options (Right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−100K sh	—	—	0
2020-02-20	Dermira, Inc.Employee Stock Options (Right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−63.8K sh	—	—	0
2020-02-20	Dermira, Inc.Employee Stock Options (Right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−65K sh	—	—	0
2020-02-20	Dermira, Inc.Restricted Stock UnitD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−6,378 sh	—	—	0
2020-02-20	Dermira, Inc.Restricted Stock UnitD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−30K sh	—	—	0
2019-08-15	Dermira, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−1,582 sh	$7.91	−$12.5K	25,401
2019-08-15	Dermira, Inc.Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−3,189 sh	—	—	6,378
2019-08-15	Dermira, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+3,189 sh	—	—	26,983
2019-06-23	FIVE PRIME THERAPEUTICS, INC.Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2019-05-17	Dermira, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−10.4K sh	$10.50	−$109K	23,794
2019-05-17	Dermira, Inc.Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−30K sh	—	—	30,000
2019-05-17	Dermira, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+30K sh	—	—	34,168
2019-02-12	Dermira, Inc.Restricted Stock UnitA Award	Chief Commercial Officer	AAward	+15K sh	—	—	15,000
2019-02-12	Dermira, Inc.Employee Stock Options (Right to buy)A Award	Chief Commercial Officer	AAward	+65K sh	—	—	65,000
2018-08-15	Dermira, Inc.Restricted Stock UnitM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−1,063 sh	—	—	9,567
2018-08-15	Dermira, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+1,063 sh	—	—	2,984
2018-08-15	Dermira, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−368 sh	$9.58	−$3,525.44	2,616
2018-08-15	Dermira, Inc.Restricted Stock UnitA Award	Chief Commercial Officer	AAward	+60K sh	—	—	60,000
2018-02-15	Dermira, Inc.Restricted Stock UnitA Award	Chief Commercial Officer	AAward	+10.6K sh	—	—	10,630
2018-02-15	Dermira, Inc.Employee Stock Options (Right to buy)A Award	Chief Commercial Officer	AAward	+63.8K sh	$28.25	+$1.8M	63,750
2017-01-09	Dermira, Inc.Employee Stock Options (Right to buy)A Award	Chief Commercial Officer	AAward	+100K sh	—	—	100,000

Recent filings

Accepted (ET)
Jun 264
Lyons-Williams Lori0001628280-26-045843
SEC(opens sec.gov)
Mar 54
Lyons-Williams Lori0001693564-26-000003
SEC(opens sec.gov)
Feb 24
Lyons-Williams Lori0001693564-26-000002
SEC(opens sec.gov)
Jun 264
Lyons-Williams Lori0001437749-25-021367
SEC(opens sec.gov)
Jun 24
Lyons-Williams Lori0001415889-25-015216
SEC(opens sec.gov)
May 294
Lyons-Williams Lori0001437749-24-018620
SEC(opens sec.gov)
May 234
Lyons-Williams Lori0001415889-24-014377
SEC(opens sec.gov)
May 254
Lyons-Williams Lori0001209191-23-032294
SEC(opens sec.gov)
May 264
Lyons-Williams Lori0001209191-22-032316
SEC(opens sec.gov)
Nov 104
Lyons-Williams Lori0001209191-21-064001
SEC(opens sec.gov)
Apr 194
Lyons-Williams Lori0001209191-21-027397
SEC(opens sec.gov)
May 154
Lyons-Williams Lori0001209191-20-029794
SEC(opens sec.gov)
Feb 244
Lyons-Williams Lori0001562180-20-001624
SEC(opens sec.gov)

Companies

Address

3565 GENERAL ATOMICS COURT, SUITE 200

SAN DIEGO, CA, 92121